Home Cart Sign in  
Chemical Structure| 94079-81-9 Chemical Structure| 94079-81-9

Structure of Poliumoside
CAS No.: 94079-81-9

Chemical Structure| 94079-81-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Poliumoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Poliumoside

CAS No. :94079-81-9
Formula : C35H46O19
M.W : 770.73
SMILES Code : O(C(/C=C/C1=CC(O)=C(O)C=C1)=O)[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](OCCC4=CC(O)=C(O)C=C4)O[C@@H]2CO[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5
MDL No. :MFCD23160017

Safety of Poliumoside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human microvascular endothelial cells (MVECs) 30 micromolar 24 hours Poliumoside did not activate the Nrf2 cell defense pathway, did not induce expression of Nrf2 target genes, and did not promote nuclear translocation of Nrf2. J Ethnopharmacol. 2016 Dec 4;193:397-407
A549 cells 10, 20, 40 µM 24 hours To evaluate the protective effects of POL against TNF-α-induced damage in A549 cells. Results showed that POL dose-dependently attenuated TNF-α-induced IL-1β, IL-6, and IL-8 production, cell apoptosis, the expression of apoptosis-related genes (Caspase 3, Caspase 8, and Caspase 9), and ROS activity. Front Pharmacol. 2021 Jul 7;12:693983

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Spinal cord injury model Intraperitoneal injection 20 or 40 mg/kg Once daily for 1 week To evaluate the therapeutic effects of Poliumoside on spinal cord injury, results showed that Poliumoside improved neural pathology and motor function recovery. Theranostics. 2025 Mar 18;15(9):4188-4211

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.30mL

0.26mL

0.13mL

6.49mL

1.30mL

0.65mL

12.97mL

2.59mL

1.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories